Katerina Leftheris

Sunesis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index1.9kcitations71works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(20), Synthesis and biological activity(11), Computational Drug Discovery Methods(9), Protein Kinase Regulation and GTPase Signaling(6), Synthesis and Characterization of Heterocyclic Compounds(5)

Publications71 total

Correction to “Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005”
Journal of Medicinal Chemistry·2024
MACROCYCLES IN DRUG DISCOVERY
Medicinal chemistry reviews·2024
Empowering Voices: Inspiring Women in Medicinal Chemistry
Journal of Medicinal Chemistry·2024· 2 citedOpen Access
Empowering Voices: Inspiring Women in Medicinal Chemistry
ACS Medicinal Chemistry Letters·2024Open Access
Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI)
Journal of Medicinal Chemistry·2023· 3 cited
Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI)
ACS Medicinal Chemistry Letters·2023· 3 citedOpen Access
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Respiratory Research·2021· 83 citedOpen Access
Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity
Journal of Medicinal Chemistry·2021· 7 citedOpen Access
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005
Journal of Medicinal Chemistry·2021· 7 citedOpen Access
PLN-74809, a clinical-stage, dual alphaVbeta6/alphaVbeta1 integrin inhibitor, reduces fibrosis in a preclinical model of biliary fibrosis and precision-cut liver slices from primary sclerosing cholangitis and primary biliary cholangitis patients
Journal of Hepatology·2020· 1 cited
PLN-74809, A Dual α <sub>V</sub> β <sub>6</sub> /α <sub>V</sub> β <sub>1</sub> , Oral, Selective Integrin Inhibitor, Is Well Tolerated and Reduces Lung TGF-β Activity in Healthy Volunteers
2020· 2 citedOpen Access
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Journal of Medicinal Chemistry·2020· 205 citedOpen Access
Discovery of CRBNE3 Ligase Modulator CC-92480 forthe Treatment of Relapsed and Refractory Multiple Myeloma
Figshare·2020Open Access
Insights into Protein–Ligand Interactions in Integrin Complexes: Advances in Structure Determinations
Journal of Medicinal Chemistry·2020· 39 citedOpen Access
Recent Advances in the Development of Small-Molecule Inhibitors for Idiopathic Pulmonary Fibrosis (IPF)
Medicinal chemistry reviews·2019· 1 cited
Dual aVß6/aVß1 inhibitor PLN-74809 blocks multiple TGF-ß activation pathways associated with IPF
2019· 5 cited
Dual α <sub>V</sub> β <sub>6</sub> /α <sub>V</sub> β <sub>1</sub> Inhibitor PLN-74809 Reduces Fibrogenesis in Ex Vivo and In Vivo Models of IPF
2019· 1 cited
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy
Journal of Medicinal Chemistry·2019· 17 citedOpen Access
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen
Journal of Medicinal Chemistry·2017· 59 citedOpen Access
Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor
Bioorganic & Medicinal Chemistry·2017· 16 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Joel C. Barrish(17), John H. Dodd(16), Gary L. Schieven(15), John Hynes(13), Kim W. McIntyre(13), Sidney Pitt(13), Arthur M. Doweyko(13), Kathleen M. Gillooly(12), John S. Sack(12), Murray McKinnon(12), Stephen T. Wrobleski(11), David J. Shuster(10), Alaric J. Dyckman(9), Shuqun Lin(9), Ding Ren Shen(9), Rosemary Zhang(9), Susan E. Kiefer(9), Hongjian Zhang(9), Kevin Kish(9), Chunjian Liu(8)